🚨 Exiting start to 2026 for the @SIFT_RCT 🚀 50 patients included in Norway 🇳🇴 and hopefully expansion to other Skandinavian countries 🇩🇰🇸🇪🤩 Thanks to all PIs and great colleagues for our collaboration ❤️🙏

Official FDA communication on withdrawal of andexanet alfa. fda.gov/vaccines-blood-biolo…

Is Exclusion of Patients on Oral Anticoagulants From IV Thrombolysis Really Necessary? In this #BloggingStroke post, @JohannaSeidenMD discusses #Stroke article by @TotoMynell et al. ahajournals.org/do/10.1161/b…

🚨 Missed it? Catch up on the Stroke Alert Podcast featuring @TotoMynell on the DO-IT Target Trial Analysis — key insights into thrombolysis in DOAC-treated stroke patients. Don’t miss this one! 🎧 Stroke Alert October 2025 strokealert.libsyn.com/strok…

In a systematic review and study-level meta-analysis, TNK improved excellent functional outcomes and recanalization in AIS patients treated within 4.5-24 hours, without increasing the risks of sICH or mortality. #stroke ahajrnls.org/4nMEfSn

@SIFT_RCT update at Bergenkonferansen by PhD candidate Kim L Schultz 👏🚦🧠 Great to be a part of the Norwegian Stroke Organization board, looking forward to meeting up in Bergen next year, celebrating the 30th anniversary of this important meeting point for Norwegian stroke physicians🤩🙏 Sign up!

Top recruiting center in the @SIFT_RCT Vestfold Hospital Trust 👏 7th patient so far, impressive work @EnidaDB Håvard Lisether and team🚦🧠🤩

Administering a Second Dose of Intravenous Tenecteplase in Acute Ischemic Stroke: Rationale and Design of a Pilot Clinical Trial | Stroke: Vascular and Interventional Neurology ahajournals.org/doi/10.1161/… @StrokeAHA_ASA @SVINJournal @svinsociety

The evidence that it is safe to give IV thrombolysis for AIS patients on DOACs continues to build. This Australia New Zealand study used target trial emulation methodology to simulate an RCT. Stroke patient on DOAC therapy who received IVT had significantly better MRS 0–2 outcomes than those who did not, and actually had a lower risk of ICH (albeit non significant). Have you ever given TPA or TNK to a patient on a DOAC? ahajournals.org/doi/abs/10.1…

Great news! New trial sites for SIFT has opened at @VestreViken Drammen and @SInnlandet Lillehammer🙏Looking forward to our collaboration @AnetteHuuse

Atrial fibrillation patients can still suffer a stoke while on DOACs. 𝐒𝐡𝐨𝐮𝐥𝐝 𝐰𝐞 𝐬𝐰𝐢𝐭𝐜𝐡 𝐭𝐨 VKA, 𝐭𝐫𝐲 𝐚 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐃𝐎𝐀𝐂, 𝐨𝐫 𝐬𝐭𝐢𝐜𝐤 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐬𝐚𝐦𝐞? A thread on our meta-analysis, out now in @GreenJournal neurology.org/doi/10.1212/WN…

Patient included at @StOlavshospital ! Congrats to study team, great work🚀☀️🙏@FIldstad @HanneEllekj

#STROKE: In a multicenter target trial analysis of patients with recent DOAC intake, IVT was linked to better outcomes and no excess bleeding vs. no IVT group. More trial data is needed.💉 #AHAJournals ahajournals.org/doi/full/10.…

Soon we will ALL be giving IV TNK to stroke patients on DOACS. The drumbeats are pounding. Here is yet another comparative effectiveness study showing lower ICH and better mRS outcomes among DOAC pts given lytics compared to those who did not. ahajournals.org/doi/abs/10.1…

Most viewed this week from @JAMANeuro: APOE epsilon ε4 is a significant risk factor for intracranial hemorrhage in patients with atrial fibrillation on apixaban. ja.ma/3TJHNb8

Great news☀️! First patient included at @UNN Tromsø. Congratulations @AgnetheElt26097 and team🙏

🚀Great news! New trial site for SIFT has opened at Stavanger universitetssykehus. Looking forward to our collaboration @SoffienA 🤩💊🧠

First patient included at Sykehuset i Vestfold Tønsberg @EnidaDB and Håvard Lisether🤩💊🧠 Congrats, great work🙏

🚀Great week for the SIFT trial! New trial site opened at @StOlavshospital 🤩Impressive study team 🙌 Fredrik Ildstad!

🚀Great news! New trial site for SIFT has opened at Sykehuset i Vestfold Tønsberg. Looking forward to our collaboration @EnidaDB and Håvard Lisether🤩💊🧠